| アブストラクト | Whether or not vascular endothelial growth factor pathway inhibitors (VPIs) increase the risk of artery dissection is still unknown. This study aimed to quantitatively evaluate the possibility of artery dissection as a class effect of VPIs using nationwide real-world data. This cohort study was conducted based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), which spans nearly the entire Japanese population of over 100 million individuals. We included the patients prescribed with 12 types of VPIs between 2012 and 2020. The incidence rate (IR) ratio of artery dissection for each VPI were estimated in comparison with bevacizumab, the only VPI in Japan with artery dissection listed in the package insert. Artery dissection as an outcome was targeted for acute artery dissection requiring hospitalization (including dissecting aneurysm). As a reference, a natural IR standardized by sex and age of bevacizumab-prescribed patients was also estimated using the direct method for the general population of NDB. Of 503,342 patients, the IR of artery dissection for bevacizumab was 44.4 (/100,000 person-years), and the adjusted IR ratios for each VPI compared with bevacizumab were consistently similar to or >1.0. The IRs for each VPI were also higher than the crude natural IR (1.66/100,000 person-years; 95% CI: 1.59-1.73) and the standardized natural IR (2.18/100,000 person-years; 95% CI: 1.86-2.50). Real-world evidence suggests the risk of artery dissection as a class effect of VPIs. More attention on this risk will be necessary when using VPIs in clinical practice. |
|---|
| ジャーナル名 | Clinical and translational science |
|---|
| Pubmed追加日 | 2024/12/2 |
|---|
| 投稿者 | Okui, Jun; Waki, Takashi; Kajiyama, Kazuhiro; Sawada, Sono; Watanabe, Shinya; Namba, Yukari; Kobayashi, Ayano; Kawarasaki, Shuichi; Amakasu, Kohei; Iguchi, Toyotaka; Horiuchi, Naoya; Uyama, Yoshiaki |
|---|
| 組織名 | Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo,;Japan.;Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency,;Tokyo, Japan.;Office of Regulatory Science Research, Center for Regulatory Science,;Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.;Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical;Devices Agency, Tokyo, Japan.;Center for Regulatory Science, Pharmaceuticals and Medical Devices Agency, Tokyo, |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39618058/ |
|---|
